Introduction {#s01}
============

Voltage-gated potassium channels are composed of four identical subunits, each containing a voltage-sensing domain (VSD; helices S1--S4) and a pore domain (S5 and S6) ([@bib55]; [@bib22]). The VSD S4 helix contains highly conserved basic amino acids at every third position ([Fig. 1](#fig1){ref-type="fig"}). Changes in transmembrane potential act directly on a subset of these residues (arginine residues R1--R4), causing them to move through the electric field ([@bib53]; [@bib1]; [@bib42]; [@bib54]). The movement of S4 is in turn mechanically coupled to pore domain opening and closing ([@bib6]). This mechanism of activation is generally conserved with sodium and calcium channels, two other channel types that, along with potassium channels, act to coordinate the action potential in excitable cells ([@bib5]). In addition to their role in activation, voltage-sensing arginine residues play important roles in the mechanism of modulation of voltage-gated channel function by small molecule inhibitors ([@bib3]) and by therapeutic lipids ([@bib34]). Finally, voltage-sensing arginine residues of voltage-gated channels are commonly found mutated in disease ([@bib10]). As a result, this region is a subject of intense interest.

![**Crystal structure of the K~v~ 1.2/2.1 chimera suggests electrostatic accommodation of gating charges within the voltage sensing domain.** Labels correspond to the residues at homologous positions in *Shaker.* Voltage-sensing arginine residues are shown in blue, conserved glutamate residues are shown in red, and hydrophobic residues, including the conserved phenylalanine in the hydrophobic plug (F290 in *Shaker*), are shown in green.](JGP_201812075_Fig1){#fig1}

Early studies of arginine residues in the voltage sensor of the *Shaker* potassium channel demonstrated that mutation of different positions nonequivalently affects channel activation ([@bib35]). In some positions, mutation of arginine to the charge-sparing lysine caused less-pronounced effects compared with that of charge-eliminating mutations, suggesting an explicit electrostatic role of these arginine residues in gating ([@bib35]). Indeed, crystal structures of activated (depolarized) potassium channels show these arginine residues paired with highly conserved negatively charged residues from S1 and S2 ([@bib30], [@bib31]). Contemporary structural models of potassium channel activation propose that the voltage-sensing arginine residues sequentially interact with these negatively charged residues as the S4 helix moves from an inward to outward position ([@bib19]; [@bib24]; [@bib14]). In so doing, the helix must also pass through a tight "plug" wherein the gating charges interact with conserved hydrophobic amino acids from nearby helices ([@bib54]; [@bib44]; [@bib47]; [@bib28]; [Fig. 1](#fig1){ref-type="fig"}). The lack of an atomic-scale structure of a deactivated or intermediate state of a voltage-gated channel has limited the visualization of the movements associated with voltage-sensor activation and deactivation. More fundamentally, it is not well understood whether or how the energetic contributions originating purely from electrostatic components affect the stability of specific functional states.

To quantify electrostatic effects explicitly, one would like to selectively neutralize the charge of arginine while leaving other critical features of the side chain (such as shape and polarity) unchanged. Such an approach is uniquely required to the study of the distal guanidinium groups of the S4 charges in voltage sensors, because their relationship with the surrounding domain is proposed to be akin to a permeant ion through an ion channel selectivity filter ([@bib45]; [@bib49]; [@bib43]). Neither conventional mutagenesis nor substituted cysteine modification allow for the alteration of charge without significant, concomitant changes in molecular shape. The amino acid citrulline, an uncharged arginine analogue, may better serve this purpose. This naturally occurring metabolite is present in the cytoplasm of diverse cell types; it serves as an anabolic precursor to arginine in the urea cycle ([@bib16]) and a by-product of nitric oxide synthesis from arginine ([@bib32]). This amino acid is not directly encoded because it lacks an explicit synthetase, but it is found within proteins as a result of the posttranslational deimination of arginine residues ([@bib18]). There is evidence from prior in vitro translation studies that citrulline is tolerated by the prokaryotic ribosome and stable in a cellular milieu ([@bib25]; [@bib11]). Additionally, citrulline has been substituted for arginine in the active sites of some enzymes by using chemical semisynthesis ([@bib27]; [@bib8]). Critically, citrulline retains the overall architecture of the distal guanidinium group of arginine ([Fig. 2 A](#fig2){ref-type="fig"}).

![**Encoding of citrulline into Shaker. (A)** Structural and electrostatic representations of the side chains of arginine, citrulline, and glutamine. **(B)** Currents generated from co-injection of cRNA encoding R1TAG, R3TAG, and R4TAG with CIT-tRNA compared with those injected with cRNA and full-length (pCA-ligated) tRNA in parallel. Lack of expressed current in the pCA condition for a given position is consistent with faithful encoding of citrulline. Error bars indicate SEM.](JGP_201812075_Fig2){#fig2}

Here we have used the nonsense suppression method in conjunction with chemical aminoacylation to encode citrulline into the voltage sensor of the *Shaker* potassium channel expressed in the eukaryotic *Xenopus laevis* oocyte. The observed functional effects at three different sites together suggest that citrulline substitution at these positions minimizes the penalties to activation caused by steric losses and clashes within the tight molecular pathway of the voltage sensor gating pore. In an experimental context wherein steric changes are minimized, the positive charge at R4 emerges as playing an outsized role in the deactivation of the channel.

Materials and methods {#s02}
=====================

Synthesis of citrulline-phosphodesoxycytosine phosphoadenosine {#s03}
--------------------------------------------------------------

### General information {#s04}

All solvents and reagents were supplied by Sigma Aldrich and were used as is unless explicitly stated, and phosphodesoxycytosine phosphoadenosine (pCA) was obtained through GE Healthcare/Dharmacon. Dry nitrogen was supplied by Praxair and passed through two moisture-scrubbing columns of dry calcium sulfate (Drierite) before use. HPLC analyses were performed on a Waters 1525 Binary HPLC pump equipped with a Waters 2998 Photodiode Array Detector by using Sunfire C18 analytical (3.5 µm, 4.6 × 150 mm, 0.8 ml/min) or preparative (5.0 µm, 19 × 150 mm, 10 ml/min) columns and Empower software; buffers were drawn in linear gradients from 100% A (50 mM ammonium acetate) to 100% B (acetonitrile) over 30 min. UV-visible spectra for concentration determinations were recorded on a Thermo Fisher Scientific Nanodrop 2000C spectrophotometer. Mass spectra were recorded on a Waters Q ToF Premier Quadrupole instrument, in both positive and negative modes.

### Cyanomethyl ester of Boc-[l]{.smallcaps}-citrulline {#s05}

The cyanomethyl ester of Boc-[l]{.smallcaps}-citrulline was prepared and purified as described previously ([@bib39]).

### Citrulline-pCA {#s06}

Slight modifications from the published procedure were used ([@bib39]; [@bib20]). The cyanomethyl ester of Boc-[l]{.smallcaps}-citrulline (0.04 mmol) and pCA (5 mg, 0.008 mmol) were dissolved in dry dimethylformamide (200 μl) in a screw-top vial (1 dram) and tetrabutylammonium acetate (30 mg, 0.1 mmol) was added. The solution was stoppered and stirred at room temperature and monitored by HPLC over several hours (2-µl aliquots were removed and diluted into 100 µl of a 4:1 mixture of A/B buffer before injection) with detection at 261 nm. Unreacted pCA elutes at ∼9 min, and the Boc-[l]{.smallcaps}-citrulline pCA product elutes around 10--13 min. The reaction was judged complete after consumption of free pCA, after ∼4 h. The reaction was divided equally into 8 × 1.5--ml tubes, and ∼1 ml ice-cold ether was introduced to each, resulting in a cloudy precipitate, which was centrifuged down to a pellet (10,000 rpm, 1 min). The eight pellets were then each resuspended in 50 µl acetonitrile and precipitated again with 1 ml ether. After a third round of precipitation, the eight tubes were combined into one and precipitated a fourth time, then dried in a gentle stream of dry nitrogen gas after centrifugation. Approximately 300 µl ice-cold trifluoroacetic acid was added, and the pellet was dissolved via agitation and pipetting and placed on an ice bath for 30 min to remove the Boc group. Excess trifluoroacetic acid was removed in a gentle stream of dry nitrogen gas until a sticky oil remained, and ice-cold ether was added to precipitate the trifluoroacetic acid salt of [l]{.smallcaps}-Citrulline-pCA, which was washed twice more with ether and very carefully dried in a gentle stream of dry nitrogen gas. The resulting granular powder was stored as a salt at −20°C. For ligation to −CA tRNA, this material was carefully dissolved in ∼50 µl dry DMSO and checked for product integrity via HPLC, and stock concentration was approximated on a NanoDrop UV-vis spectrometer by using the known molecular extinction coefficient for pCA. [l]{.smallcaps}-Citrulline-pCA isolated in this manner had its concentration adjusted to 3 mM with DMSO, and the stock was stored in aliquots at −28°C.

In vivo nonsense suppression in *X. laevis* oocytes {#s07}
---------------------------------------------------

Mutations were made into the WT inactivation-removed (Δ6--46) *Shaker* in the pBSTA vector by using standard methods. Complementary RNA (cRNA) was transcribed via the Ambion mMESSAGE mMACHINE T7 kit. Truncated pyrrolysine tRNA (lacking the last two nucleotides) was chemically synthesized and HPLC purified by Integrated DNA Technologies, Inc. Folding was accomplished as follows: tRNA was resuspended in 10 mM HEPES and 3 mM MgCl~2~, pH 7.5, and then moved to a thermocycler wherein a protocol was run with heating to 94°C for 3 min followed by linear cooling to 4°C over the course of 20 min. Ligation and recovery of the refolded tRNA was done as previously described in detail ([@bib29]). *X. laevis* oocytes were purchased from Ecocyte Inc. and co-injected with 25 ng cRNA bearing a TAG mutation at the site of encoding and ∼150 ng of pyrrolysine tRNA appended with either pCA-citrulline or the pCA alone as a negative control. For recording of WT *Shaker* and conventional mutations, 1--10 ng cRNA was injected. Recordings were made 20--30 h postinjection.

Electrophysiology {#s08}
-----------------

###  {#s09}

Two-electrode voltage-clamp (TEVC) recordings were made in standard Ringer's solution containing (in mM) 116 NaCl, 2 KCl, 1.8 CaCl~2~, 2 MgCl~2~, and 5 HEPES. The holding potential was −80 mV. G-V values were derived from isochronal tail currents from cells expressing at least 1 µA of tail current, for all variants except R368Q-*Shaker*, which closed too quickly to reliably quantify tail currents. In this case, we derived G-V values from ionic currents, assuming a reversal potential for potassium of −80 mV. The data we derived from R368Q was in good agreement with those published previously. Cut-open voltage-clamp (COVC) recordings from oocytes expressing Shaker variants were done as described previously ([@bib46]). Gpatch, an in-house program, controlled an SB6711 digital signal processor-based board sampling at 40 µs/point (Innovative Integration) with an A4D4 board (Innovative Integration). Oocytes were held under voltage-clamp with a Dagan CA-1B amplifier, and current was filtered at 5 kHz. All recordings were performed around 18°C, with an external solution containing (in mM) 12 potassium methylsulfonate (MES), 10 HEPES, and 2 Ca(OH)~2~ and an internal solution containing (in mM) 120 K-MES, 10 HEPES, and 2 EGTA. Both solutions were set to pH 7.5. Microelectrodes were pulled on a Flaming/Brown micropipette puller (model P-87, Sutter Instruments), were filled with 3 M KCl, and had a resistance of ∼0.2--0.8 MΩ. For both TEVC and COVC recordings, G-V values were fit to a two-state model.

### Structural depictions {#s10}

Models were made from PDB accession no. [2R9R](2R9R) by using Pymol.

Online supplemental material {#s11}
----------------------------

Fig. S1 shows mass spectrometry confirming the identity of the Citrulline-pCA substrate before ligation to tRNA.

Results {#s12}
=======

Encoding of citrulline in the voltage sensor of Shaker {#s13}
------------------------------------------------------

Substitution of arginine with citrulline was achieved by nonsense suppression with chemically aminoacylated tRNA ([@bib33]). Coinjection of citrulline-acylated pyrrolysine tRNA (Pyl-citrulline) with cRNA of *Shaker* potassium channels with TAG stop codons at R362, R368, and R371 yielded robust voltage-activated potassium currents as measured by two-electrode voltage clamp. In [Fig. 2 B](#fig2){ref-type="fig"}, we have quantified the amount of ionic current observed at +50 mV at each site, in comparison with the same cRNA co-injected with unacylated, full-length (pCA-ligated) pyrrolysine tRNA. Currents were not seen in the absence of appended amino acid, reflective of the orthogonality of this tRNA species in the *X. laevis* oocyte ([@bib21]). Ionic currents were not observed from injection of citrulline-acylated tRNA with cRNA encoding R2TAG (R365) or R6TAG (R377), signifying either that these sites were not efficiently "rescued" by Pyl-citrulline or that citrulline incorporation rendered the channels nonfunctional. Although the charge at R6 has been previously implicated in channel trafficking, R2 is tolerant of side-chain mutagenesis ([@bib35]). The specific reasons for our lack of observed current at these positions is unclear and perhaps a subject for future studies. The expression levels achieved from rescue at R1, R3, and R4 compare favorably with previous studies encoding other polar unnatural amino acids into *Shaker* ([@bib38]), enabling detailed characterization of macroscopic ionic currents but not the direct assessment of S4 movement via gating-current measurement. Therefore, the results reported here represent an indirect assessment of gating-charge function. It should be noted that gating currents have been recorded from *Shaker* channels wherein the unnatural amino acid ANAP was encoded via the evolved synthetase system, and thus the requisite expression levels are compatible with nonsense suppression per se ([@bib26]).

Effects of citrulline substitution at R1 or R3 on *Shaker* activation {#s14}
---------------------------------------------------------------------

R1 (R362) is the outermost arginine in the S4 voltage sensor of *Shaker*. During activation, this arginine has been proposed to move outward from a location near the bottom of the hydrophobic plug to the extracellular environment. In *Shaker*, conventional mutation of R362 shifts the G-V in a depolarized direction, 30--40 mV. This is true whether the side chain is neutralized with glutamine ([@bib35]) or eliminated with alanine ([@bib12]). For the purpose of comparison, we also recorded R362Q-*Shaker* and indeed, we note an ∼30 mV shift in the V~1/2~ for activation as compared with WT, and the activation slope was also decreased ([Table 1](#tbl1){ref-type="table"}). In contrast, when R362 was mutated to citrulline, the activation of the channels was similar to WT ([Fig. 3 D](#fig3){ref-type="fig"}): V~1/2~ of −19.4 ± 3.5 mV and −25 ± 1.7 mV for WT and R362Cit, respectively. Thus, the charge at position R1 is apparently expendable for channel function when side chain structure is not concomitantly altered.

###### Gating parameters for glutamine and citrulline substitution in the voltage sensor

                   ***n***   **V~1/2~**   **SD**   **Z**   **SD**
  ---------------- --------- ------------ -------- ------- --------
  WT               9         −19.4        3.5      2.8     0.7
  WT (COVC)        3         −15.4        1.4      2.1     0.2
  R362Q            5         12.0         3.0      1.5     0.1
  R362CIT          6         −25.2        1.7      2.4     0.2
  R368Q            5         79.8         3.9      1.3     0.1
  R368CIT          6         −1.4         5.3      1.5     0.3
  R371Q (COVC)     6         −29.7        3.6      2.7     0.7
  R371CIT (COVC)   6         −56.7        1.7      3.1     0.5

![**Lack of effect on activation of encoding citrulline at R1 in *Shaker*. (A--C)** Voltage-dependent ionic currents from oocytes expressing WT, R362CIT-, and R362Q-*Shaker* channels. Oocytes were held at −80 mV and subjected to 100-ms pulses in 10-mV steps, followed by 100-ms pulses to −50 mV (WT, Cit) or −40 mV (Q) before returning to the holding potential. **(D)** Normalized G-V values. Error bars represent ±SEM. At R1, a positive charge is apparently dispensable for activation, provided the shape of arginine is maintained.](JGP_201812075_Fig3){#fig3}

R3 (R368) is proposed to traverse the electric field in response to depolarization; data from structural and molecular dynamics studies suggest that this amino acid is electrostatically bonded to E0 (E247) in the activated voltage sensor. Previous studies have demonstrated that mutation of R368 to either glutamine or alanine results in \>70-mV shifts in the G-V to the right ([@bib37]; [@bib12]), but mutation to asparagine or methionine ([@bib1]; [@bib42]) causes only minor effects. From these data, steric and electrostatic roles for arginine can be suggested but not well quantified. In our hands, the V~1/2~ for activation for the R368Q mutant was shifted ∼100 mV to the right relative to WT *Shaker*, and the activation slope was significantly shallowed ([Fig. 4 C](#fig4){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). When we instead encoded citrulline into this site, the V~1/2~ for activation was modestly affected with an ∼18-mV shift rightward compared with WT *Shaker*. Interestingly, although there was a 78-mV difference in the activation midpoints between R3Cit and R3Q, the activation slope of R3Cit was shallowed to a similar degree as R3Q ([Table 1](#tbl1){ref-type="table"}). These data are indeed consistent with a net electrostatic effect of the R3 positive charge on voltage dependence of activation, although the effect attributable to charge is significantly milder than when shape is concomitantly altered. Thus, in addition to enabling a quantification of electrostatic contributions to channel function, the data from R1 and R3 highlight the extent to which changes in the shape of arginine at these positions cause strong deleterious effects within this voltage sensor.

![**Effects on activation of encoding citrulline at R3 in *Shaker***. **(A and B)** Voltage-dependent ionic currents from oocytes expressing R368CIT- and R368Q-*Shaker* channels. Oocytes were held at −80 mV and subjected to 100-ms pulses in 10-mV steps, followed by 100-ms pulses to −40 mV (Cit) or −30 mV (Q) before returning to the holding potential. **(C)** Normalized G-V values. Error bars represent ±SEM. Note that the same WT data are used here and in [Fig. 3 D](#fig3){ref-type="fig"}. At R3, neutralization via citrulline resulted in a rightward shift and change in activation slope, suggesting that a positive charge at this position is necessary for normal activation. However, the effect on activation is modest compared with mutation to glutamine.](JGP_201812075_Fig4){#fig4}

Effect of encoding citrulline into R4 {#s15}
-------------------------------------

Within the S4 voltage sensor, R4 (R371 in *Shaker*) is the most cytoplasmic arginine to cross the hydrophobic plug during activation ([@bib54]). Mutation of this residue to glutamine has been reported to generate a small hyperpolarizing left shift in G-V ([@bib42]), although elimination of the side chain via alanine substitution generates a larger leftward shift ([@bib12]). Interestingly, mutation of R371 to lysine causes a large (\>60 mV) depolarizing rightward shift in G-V ([@bib35]). The large functional effect of this conservative mutation may be caused by an alteration in the interaction of this amino acid with the highly conserved F290 in the hydrophobic plug ([@bib28]). During initial TEVC recordings, we noted a large hyperpolarized shift in the resting membrane potential of R371Cit-expressing cells (−76 ± 5 mV in R371Cit versus −41 ± 5 mV for WT *Shaker*), consistent with a standing potassium conductance. We therefore decided to record this and related variants using the cut-open voltage-clamp technique, which allows control of intracellular as well as extracellular ionic composition ([@bib46]). By using this configuration, R371Q-*Shaker* demonstrated a left shift in V~1/2~ of ∼14 mV ([Fig. 5 D](#fig5){ref-type="fig"}). In contrast, when citrulline was encoded, the G-V relationship was shifted significantly further to the left (−ΔV~1/2~ of ∼41 mV). Both activation and deactivation kinetics were affected by neutralization of R371 with Citrulline; activation was slowed three- to fourfold depending on the test voltage, and deactivation kinetics were profoundly slowed between 50- and 100-fold ([Fig. 5, E and F](#fig5){ref-type="fig"}).

![**Outsized electrostatic role for R4 in channel deactivation. (A--C)** Normalized G-V curves from COVC of WT-, R371Q-, and R371Cit-*Shaker.* Oocytes were held at −80 mV, then prepulsed to −120 mV for 200 ms, before a variable pulse ranging from 80 mV to −120 mV, followed by a postpulse to −120 mV, before returning to the original holding potential. **(D)** Normalized G-V values. Error bars represent ±SEM. **(E)** A comparison of the activation rate (τ) between WT- and R371Cit-*Shaker* as derived from the same data used for the G-V curves. **(F)** Deactivation rate for WT- and R317Cit-*Shaker*. For these data, oocytes were held at −80 mV, prepulsed to −120 mV for 200 ms, then pulsed to 80 mV for 50 ms, followed by a variable pulse ranging from 80 mV to −120 mV for 350 ms, before returning to the original holding potential.](JGP_201812075_Fig5){#fig5}

Discussion {#s16}
==========

Here we report the first examples of in vivo site-directed encoding of citrulline, a neutral analogue of the canonical amino acid arginine. We substituted the conserved arginine residues in the voltage sensor of *Shaker*, a model voltage-gated potassium channel. In the case of R1Cit and R3Cit, we noted modest defects compared with respective glutamine and alanine mutations ([@bib12]). These results support the idea that in the voltage-sensing domain, a crowded structural environment around S4 has evolved to accommodate the guanidinium moieties of the arginine residues, and that altering the precise lock-and-key nature of this fit results in defects in activation that are not completely related to changes in charge. The behavior of R1Cit was essentially identical to WT *Shaker*, which leads us to conclude that a positive charge at R1 is dispensable for normal channel function. However, it is important to note that this interpretation does not exclude the possibility that R1 interacts with negatively charged amino acids during various resting, intermediate, or active conformations. Instead, the data indicate that any such interactions, in aggregate, do not have major effects on channel activation. It should also be noted that the slope of the G-V curve, as measured here, does not give the real charge contribution of R1 to the gating current because it has not been measured at low-enough open probability. Nonetheless, our data may provide one explanation as to why R1 is not universally conserved in potassium channel voltage-sensing domains. In contrast to R1, R3Cit was right shifted relative to WT *Shaker*, although not as substantially as with glutamine or alanine. This result is consistent with the notion that a positive charge at this position plays a role in activation in the native channel, as proposed in prior work ([@bib48]).

The neutralization of R4 (R371) via citrulline strongly hyperpolarized the activation midpoint, and it slowed activation and drastically slowed deactivation kinetics. One mechanistic explanation for the energetic and kinetic effects of neutralization of R4 emerges from a consideration of the positioning of gating charges in the activated versus the deactivated states of the voltage sensor. Functional and computational experiments support the idea that the electric field across the voltage-sensing domain is narrowly focused over a region of \<5 Å ([@bib4]; [@bib2]; [@bib7]; [@bib9]), and it is centered on the hydrophobic plug containing F290 at its most intracellular portion. Transfer across this hydrophobic region is expected to be energetically unfavorable for large, polar amino acids such as arginine ([@bib41]). During activation, this energetic barrier is overcome by voltage directly acting on charged amino acids within the electric field. In the case of citrulline substitution at R4, the first three arginines are expected to cross quickly; however, with Cit in the fourth position, the shape and polarity of arginine is preserved, but the site would no longer be expected to sense voltage. Therefore, regardless of direction, movement through the hydrophobic plug would be expected to be slowed for R4Cit. Because the opening and closing of the gate occurs only when R4 moves ([@bib28]), the ionic conductances will be slowed down ([Fig. 5, E and F](#fig5){ref-type="fig"}), even though the other three charges may translocate normally. Spectroscopic, cross-linking, and structural studies indicate that R4 is intracellular to the electrical field in the hyperpolarized, inactive state of the voltage sensor ([@bib36]; [@bib19]; [@bib17]). Conversely, in the active state, the position of R4 places it within the electric field ([@bib31]); during deactivation, it may drive the downward movement of S4 in response to hyperpolarization. The effect of neutralization of R4 may thus be more prominent on deactivation than activation. The data are equally consistent with the possibility that specific electrostatic interactions with R4 (potentially in the resting state of the VSD) play a role in catalyzing S4 movement or that loss of charge at R4 may fundamentally alter its interaction with the hydrophobic plug and that, in either case, neutralization more profoundly affects deactivation compared with activation.

In this study, citrulline was used as an analogue to quantify the effects of loss of positive charge on voltage-sensing arginine residues in a voltage-gated potassium channel. In recent years, citrullination (the posttranslational deimination of arginine residues) has been detected in an ever-increasing number of targets ([@bib52]). Research in this area is currently focused on extracellular targets wherein citrullination causes autoimmune diseases ([@bib40]; [@bib50]) and on the role of citrullination of arginine residues in controlling gene transcription ([@bib13]; [@bib51]). Thus far, mass spectroscopy identification of intracellular targets has focused on small soluble proteins; thus, there is a paucity of identified citrullinated sites within integral membrane proteins. However, VDAC1, a voltage-dependent and weakly anion-selective channel, has been shown to be citrullinated in disease states in both the brain and the heart ([@bib23]; [@bib15]). As the citrulline proteome continues to expand and more integral membrane proteins are identified, the ability to encode citrulline in vivo in a site-specific manner may prove a valuable tool to understand the functional effects of this posttranslational modification.
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